Metabolism

Describe the mechanisms of drug clearance and metabolism.

Removal of drug from the body requires either:

  • Metabolism of active drug to an inactive substance
    Typically by the liver, but other organs (kidney, lungs) also metabolise some substances.
  • Excretion of active drug
    Often by the kidneys, but may also be in bile, or exhaled.
    • Removal of drugs from the body is achieved predominantly through renal excretion of water-soluble compounds
    • As many drugs are lipophilic, metabolism to water soluble compounds is required to clear drugs from the body

Clearance

Clearance describes the elimination of drug from the body. Clearance is:

  • The volume of plasma completely cleared of a drug per unit time
    Measured in ml.min-1.
  • Does not include redistribution
  • Is calculated from the area under the concentration time curve:

Total clearance is the sum of clearances from individual organs, e.g.:

  • , where:
    • , where:
      • is urine concentration in mmol.L-1
        Function of glomerular filtration, reabsorption, and secretion.
      • is the urine flow in ml.min-1
      • is the plasma concentration in mmol.L-1
    • , where:
      • is the hepatic blood flow in ml.min-1
      • is the extraction ratio

Kinetics

Drug clearance can follow either first order or zero-order kinetics:

  • First-order Kinetics
    A constant proportion of the drug in the body is eliminated per unit time.
    • Most drugs are eliminated by first order kinetics, as the capacity of the elimination system exceeds the concentration of drug

  • Zero-order kinetics
    A constant amount of drug is eliminated per unit time, independent of how much drug is in the body.
    • Occurs when there is saturation of enzyme systems
      It is also known as saturation kinetics for this reason.
      • e.g. Phenytoin follows first order kinetics at lower doses, but zero-order kinetics at doses within the therapeutic range
        This is clinically relevant as the narrow therapeutic index means that toxic levels may occur rapidly with a small increase in dose.
      • e.g. Ethanol also follows zero-order kinetics within the "therapeutic range", as it is a very weak (doses are in grams) positive allosteric modulator of the GABAA receptor
    • Zero-order kinetics is concerning as:
      • Plasma concentrations will rapidly increase with only modest dose increase
      • There is essentially no steady state: if drug input exceeds output, plasma levels will continue to rise

Michaelis-Menten

The Michaelis-Menten equation describes the transition from first order to zero order kinetics as drug concentration increases:

  • Metabolism increases proportionally with concentration as long as the concentration of drug leaving the organ of metabolism (e.g. in the hepatic vein) is less than half of the maximal concentration of drug that organ can metabolise
    • This is ~1/3rd of the maximal rate of metabolism

Hepatic Metabolism

The principle organ of drug metabolism is the liver. Hepatic metabolism:

  • Usually decreases the function of a drug, though:
    • Prodrugs have increased pharmacologically activity after liver metabolism
    • Some drugs have active or toxic metabolites
  • Can be divided into two phases

Phase I

Phase one reactions:

  • Occur in the endoplasmic reticulum
  • Improve water solubility by exposing a functional chemical group
  • Typically occur prior to phase II reactions for most drugs
  • Include:
    • Oxidation
      Loss of electrons.
      • Main phase I reaction
      • CYP450 driven
    • Reduction
      Gain of electrons.
      • CYP450 driven
    • Hydrolysis
      Addition of a water molecule, which may result in two new compounds.
      • Esterase driven
        Therefore rapid, high capacity, organ-independent elimination.
        • Butylcholinesterase
        • Non-specific plasma cholinesterase
        • RBC estearse

CYP450 System

CYP450 enzymes are:

  • A superfamily of enzymes vital in drug metabolism
  • Named after the wavelength of light they absorb when:
    • Reduced
    • Combined with CO
  • Located in:
    • Liver
      Endoplasmic reticulum of hepatocytes.
    • Lungs
    • Kidney
    • Gut
    • Brain
  • Over 1000 enzymes, with ~50 functionally active
  • Classified by the degree of shared amino-acid sequence into:
    • Families
      CYP1, CYP2, CYP3...
    • Subfamilies
      CYP1A, CYP1B...
    • Isoforms
      CYP1A1, CYP1A2...
CYP2B6 CYP2C9 CYP2C19 CYP2D6 CYP2E1 CYP3A4 CYP3A5
Propofol Propofol, Parecoxib, Warfarin Diazepam, Omeprazole, Clopidogrel, Phenytoin Codeine, Metoprolol, Flecainide Volatile anaesthetic agents, parcetamol Common benzodiazepines, Fentanyl, Alfentanil, Lignocaine, Vecuronium Diazepam

Key CYP enzymes include:

  • CYP2E1
    Metabolises volatiles and paracetamol.
  • CYP3A4
    Responsible for 60% of metabolic activity.
  • CYP2D6
    • Important because genetic polymorphism leads to significant inter-patient variability
      May result in significant over- or under-metabolism of drugs, and therefore significant inter-individual variability in response.
      • 5-10% of the population are poor metabolisers
      • 2-10% are intermediate metabolisers
      • 1-2% are ultra-rapid metabolisers
      • Bulk of the population (70-90%) are extensive metabolisers
    • Clinical effect will depend on the type of drug
      • Pro-drugs
        • Extensive/ultra-rapid metabolisers will convert more drug to the active form, and see a greater effect
          May lead to overdose.
        • Poor metabolisers will excrete more pro-drug prior to metabolism, and see a reduced clinical effect
      • Active drug
        • Extensive/ultra-rapid metabolisers will inactivate more drug, and see a reduced effect
        • Poor metabolisers will see a prolonged clinical effect
    • Clinical effect may be altered by enzyme interactions
      • e.g. Oxycodone use by an ultra-fast metaboliser, in combination with a CYP3A4 inhibitor (e.g. diltiazem) will result in a significant increase in the clinical effect of oxycodone
    • Drugs metabolised by CYP2D6 include:
      • Analgesics
        • Codeine (prodrug)
        • Oxycodone (metabolised to the significantly more potent oxymorphone)
        • Methadone
        • Tramadol (metabolised to form with greater MOP selectivity)
      • Psychiatric drugs
        • SSRIs
        • TCAs
        • Haloperidol
      • Cardiovascular drugs
        • Amiodarone
        • Flecainide
        • Mexilitine

Phase II

Phase II reactions:

  • Involve conjugation with another compound, producing a highly polar metabolite
    This increases water solubility and therefore renal elimination.
  • Typically occur in the hepatic endoplasmic reticulum
  • Include:
    • Glucuronidation
      Addition of glucuronic acid.
    • Sulfation
      Addition of a sulfo group.
    • Acetylation
      Addition of an acetyl group.
      • Also occurs in the lung and spleen.
    • Methylation
      Addition of a methyl group.

Extraction Ratio

Extraction ratio is the proportion of a drug that is cleared from circulation during each pass through the organ, typically the liver:

Extraction ratio is dependent on:

  • Blood flow
  • Hepatocyte uptake
  • Enzyme capacity
    Described by the Michaelis Constant: The concentration of a substrate which causes an enzyme to work at 50% of its maximum capacity.

Drugs can have either a high or low extraction ratio:

  • High extraction ratio
    These drugs have a rapid uptake and high capacity, so elimination is perfusion dependent.
    • Free drug is rapidly removed from plasma, bound drug is released from plasma proteins and a concentration gradient is maintained
    • Metabolism of drugs with a high extraction ratio is:
      • Independent of protein binding
      • Dependent on liver flow
        Typically doubling liver blood flow will double hepatic clearance.
    • There is a high variability in plasma concentration between individuals due to the variation in liver blood flow
    • Drugs with high extraction ratios are generally independent of enzyme activity - decreasing enzyme activity from 99% to 95% has a minimal effect on hepatic clearance
      • The key exception is first pass metabolism, as the above change will result in a five-fold difference in dose reaching the systemic circulation
        Therefore drugs with a high extraction ratio have low PO bioavailability.
  • Low extraction ratio
    Elimination is capacity-dependent.
    • Amount of free drug available for metabolism is greatly affected by the degree of protein binding
    • Metabolism is:
      • Largely independent of flow
        Drugs have good PO bioavailability.
      • Dependent on hepatocyte function and protein binding

Factors Affecting Hepatic Metabolism

Drug Factors Patient Factors
Lipid solubility Age
Ionisation Obesity
Protein binding Pregnancy
Enzyme competition Genetics: Slow vs. fast acetylators
Hepatic flow/Extraction Ratio
Enzyme Inhibition/Induction
Hepatic disease
Smoking, ETOH

Organ Independent Metabolism

Mechanisms of organ indepedent metabolism include:

  • Hofmann Degradation
    Spontaneous degradation or metabolism of substances occurring in plasma.
    • e.g. Cisatracurim undergoes Hofmann degradation
  • Plasma Esterases
    Plasma esterases are non-microsomal enzymes which hydrolyse ester bonds. They:
    • Are typically synthetised in the liver and erythrocytes
    • Have a high capacity
      This, combined with the organ-independent elimination, means drugs metabolised by plasma esterases have a reliable offset.
    • e.g. Suxamethonium is hydrolysed by plasma esterases

References

  1. Peck TE, Hill SA. Pharmacology for Anaesthesia and Intensive Care. 4th Ed. Cambridge University Press. 2014.
  2. Essential pharmacology for the ANZCA primary exam
  3. Birkett, DJ. Pharmacokinetics made easy 9: Non-linear pharmacokinetics. 1994. Australian Prescriber.
Last updated 2017-10-03

results matching ""

    No results matching ""